Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Short-Term Debt: ¥675 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688266 Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
70 GF Score
Price ¥117.99
GF Value ¥222.27
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Suzhou Zelgen Biopharmaceuticals Co Short-Term Debt?

Suzhou Zelgen Biopharmaceuticals Co SHSE:688266 +0.53% 70 Short-Term Debt is ¥675 Mil as of Jun. 2026. GuruFocus rates SHSE:688266 with a GF Score™ of 70/100 and a GF Value™ of ¥222.27 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Suzhou Zelgen Biopharmaceuticals Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥675 Mil.

Suzhou Zelgen Biopharmaceuticals Co's quarterly Short-Term Debt declined from Dec. 2025 (¥989 Mil) to Mar. 2026 (¥843 Mil) and declined from Mar. 2026 (¥843 Mil) to Jun. 2026 (¥675 Mil).

Suzhou Zelgen Biopharmaceuticals Co's annual Short-Term Debt increased from Dec. 2023 (¥795 Mil) to Dec. 2024 (¥952 Mil) and increased from Dec. 2024 (¥952 Mil) to Dec. 2025 (¥989 Mil).

Suzhou Zelgen Biopharmaceuticals Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Suzhou Zelgen Biopharmaceuticals Co Short-Term Debt Related Terms

Suzhou Zelgen Biopharmaceuticals Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Zelgen Biopharmaceuticals Co Short-Term Debt Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.81 390.79 795.17 951.86 989.05

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 976.36 966.95 989.05 843.00 674.86
SHSE:688266
70GF Score
Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥675 Mil mean?
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Short-Term Debt of ¥675 Mil as of Jun. 2026.
Is Suzhou Zelgen Biopharmaceuticals Co's Short-Term Debt too high?
Suzhou Zelgen Biopharmaceuticals Co's current Short-Term Debt is ¥675 Mil. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Short-Term Debt compare to VRTX and REGN?
Suzhou Zelgen Biopharmaceuticals Co's Short-Term Debt of ¥675 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Suzhou Zelgen Biopharmaceuticals Co's current Short-Term Debt is ¥675 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥222.27, compared to a current price of ¥117.99 — trading 46.9% below its estimated fair value. The current Short-Term Debt is ¥675 Mil. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Short-Term Debt is ¥675 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥117.99 is trading 46.9% below its estimated GF Value™ of ¥222.27. GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for SHSE:688266:

  • Short-Term Debt: ¥675 Mil
  • GF Value™: ¥222.27 vs. price of ¥117.99 (46.9% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Suzhou Zelgen Biopharmaceuticals Co Business Description

Address No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
70GF Score

Get the complete analysis for SHSE:688266

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥117.99
Price
¥222.27
GF Value